10-Q · May 7, 2026
Quoin Pharmaceuticals reported no revenue for Q4 2026, while it incurred a net loss of approximately $5 million, compared to a loss of about $3.8 million in the same quarter last year. Operating expenses increased by…
Earnings analysis · 10-Q
QNRX earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q sections do not include the consolidated statements of operations, balance sheets, or cash flows, so revenue, margins, EPS, cash flow, debt, inventory, and receivables trends cannot be reliably…
Read full summary
The extracted 10-Q sections do not include the consolidated statements of operations, balance sheets, or cash flows, so revenue, margins, EPS, cash flow, debt, inventory, and receivables trends cannot be reliably quantified from the filing text provided. The principal update is a severe liquidity warning: as of June 30, 2026, Quoin had $3.8 million of cash and cash equivalents, $7.0 million of investments, and an $81.3 million accumulated deficit, with substantial doubt about continuing as a going concern for at least one year. No quantitative company guidance is provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls Remained Effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026, and reported no changes during the quarter that materially affected internal control over financial reporting.
What to watch
-
Substantial Going-Concern Risk
Quoin reported an accumulated deficit of $81.3 million, cash and cash equivalents of $3.8 million, and investments of $7.0 million as of June 30, 2026. Management concluded there was substantial doubt about the company’s ability to continue as a going concern for at least one year from the filing date.
-
Additional Financing Required
The company states it must raise additional capital through equity, debt, strategic relationships, grants, or other arrangements to support operations. Failure to improve liquidity could require curtailing or ceasing operations and realizing assets outside the normal course of business.
-
Revenue Generation Deferred
Quoin does not expect to generate product-sale revenue unless it completes development and obtains marketing approval for a product candidate, a process management expects to take a number of years and describes as subject to significant uncertainty.
Management's outlook
No quantitative revenue or EPS guidance is provided in the extracted 10-Q sections; the filing states that product-sale revenue is not expected unless and until marketing approval is obtained, which is expected to take a number of years.
Earlier filings 4
10-K · March 26, 2026
Quoin Pharmaceuticals is a late-stage specialty pharma focused on QRX003 for Netherton Syndrome (NS) and other rare skin diseases; QRX003 is in pivotal/late-stage clinical testing under an open IND and the company has…
10-Q · August 7, 2025
Q2 2025 10-Q shows accelerating R&D activity but worsening cash runway and a formal going-concern warning. Net loss for the quarter was $3,695,938 (loss per ADS $6.28) with R&D expense jumping to $2,050,585 as clinical…
10-Q · May 13, 2025
Quoin Pharmaceuticals reported a Q1 2025 net loss of $3,812,179 (loss per ADS $6.50) with research and development expense accelerating to $2,374,139 from $885,298 a year earlier. Cash and short-term investments totaled…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.